focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Regulatory News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

7 Mar 2022 16:00

RNS Number : 9118D
ReNeuron Group plc
07 March 2022
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BF5G6K95

Issuer Name

RENEURON GROUP PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights; An acquisition or disposal of financial instruments

3. Details of person subject to the notification obligation

Name

Spreadex LTD

City of registered office (if applicable)

St. Albans

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

10-Feb-2022

6. Date on which Issuer notified

16-Feb-2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

0.734800

3.035000

3.769800

2151158

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BF5G6K95

419300

0.734800

Sub Total 8.A

419300

0.734800%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

CFD/Spreadbet

1731858

3.035000

Sub Total 8.B1

1731858

3.035000%

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

Matthew Allen01727895011

12. Date of Completion

16-Feb-2022

13. Place Of Completion

UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEASDXESPAEFA
Date   Source Headline
18th Mar 20197:00 amRNSRetinal clinical trial progresses to next stage
12th Mar 20192:30 pmRNSNotification of Major Holdings
5th Mar 201912:56 pmRNSNotification of Major Holdings
5th Mar 20197:00 amRNSNotification of Major Holdings
5th Mar 20197:00 amRNSNotification of Major Holdings
28th Feb 20197:00 amRNSBlock Listing Review and Total Voting Rights
20th Feb 20197:00 amRNSPositive preliminary data in US retinal trial
31st Jan 20197:00 amRNSNew exosome production scale-up data presented
24th Jan 20197:00 amRNSFirst patient treated in US stroke trial
4th Jan 20197:00 amRNSReNeuron signs exosome collaboration
14th Dec 20187:00 amRNSInterim Results
20th Nov 20182:00 pmRNSNotification of Interim Results
18th Oct 20187:00 amRNSReNeuron's lead cell line shows further potential
28th Sep 20182:16 pmRNSDirector/PDMR Interest in Shares and Share Options
27th Sep 20183:02 pmRNSDirectors Share Purchases
19th Sep 20184:40 pmRNSSecond Price Monitoring Extn
19th Sep 20184:35 pmRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSBusiness development update
12th Sep 201811:40 amRNSResult of AGM
12th Sep 20187:00 amRNSAGM Trading Update
31st Aug 20187:00 amRNSBlock Listing Review and TVR
31st Jul 20183:25 pmRNSPosting of Annual Report & Notice of AGM
17th Jul 20187:00 amRNSNotification of Major Holdings
16th Jul 20183:39 pmRNSNotification of Major Holdings
16th Jul 20187:00 amRNSNotification of Major Holdings
13th Jul 201811:50 amRNSNotification of Major Holdings
12th Jul 20187:00 amRNSPreliminary Results
11th Jul 20187:00 amRNSSigns retinal stem cell exclusivity agreement
4th Jul 20182:15 pmRNSNotification of Preliminary Results
17th May 20187:00 amRNSCapital Markets Event
4th May 20187:00 amRNSExosome data presented at ISCT conference
30th Apr 20187:00 amRNSCapital Markets Event and Webcast
19th Apr 20187:00 amRNSWins grant for retinal cell therapy development
10th Apr 20181:00 pmRNSAppointment of US-based Chief Medical Officer
26th Mar 20187:00 amRNSProduct Development Update
1st Mar 20187:00 amRNSBlock Listing Review and TVR
16th Feb 20187:00 amRNSBlock Listing Application
13th Feb 201810:00 amRNSPositive pre-clinical data in nerve injury
26th Jan 20187:00 amRNSPhase II stroke data presented at AHA conference
23rd Jan 201811:06 amRNSApproval of Share Capital Reorganisation
11th Jan 20187:00 amRNSFurther re Share Capital Reorganisation
5th Jan 20187:00 amRNSProposed Share Capital Reorganisation
14th Dec 20177:00 amRNSInterim results
14th Dec 20177:00 amRNSStroke clinical trial regulatory approval in US
8th Dec 20177:00 amRNSReNeuron opens US office
13th Nov 201711:30 amRNSNotification of Interim Results
8th Nov 20177:00 amRNSRetinal disease clinical trial moves into Phase II
31st Oct 20177:00 amRNSPositive stroke clinical data & regulatory update
27th Oct 20177:00 amRNSWins further UK grant
11th Oct 20171:31 pmRNSPDMR Interest in Shares and Share Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.